Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 702 clinical trials
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)

The primary purpose of this study is to determine whether adding SurVaxM to standard chemotherapy with temozolomide is better than treatment with temozolomide alone for patients with newly diagnosed glioblastoma. This study is designed to compare the duration of survival in patients with newly diagnosed glioblastoma receiving temozolomide plus SurVaxM …

  • 0 views
  • 02 Dec, 2024
  • 10 locations
S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing the event rate of adenomas and second primary colorectal cancers at three years in patients previously treated for stage 0 to III colon or rectal cancer.

  • 0 views
  • 02 Dec, 2024
  • 1 location
Restrictive Use of Dexamethasone in Glioblastoma

The administration of steroids, most commonly dexamethasone (DEX), has established as standard of care during treatment of glioblastoma (GBM) and is widely used during the entire course of the disease including pre- and postoperative management, chemo- and radiotherapy.

dexamethasone
glioblastoma multiforme
immunosuppression
neurologic symptoms
  • 0 views
  • 19 Feb, 2024
  • 1 location
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

topical agents
ttfields
triamcinolone topical
glioma
glioblastoma multiforme
  • 0 views
  • 19 Feb, 2024
  • 7 locations
Niraparib/TTFields in GBM

Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).

glioblastoma
renal function
MRI
glioblastoma multiforme
karnofsky performance status
  • 0 views
  • 19 Feb, 2024
  • 1 location
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help.

selinexor
absolute neutrophil count
blood tests
ct scan
blood test
  • 0 views
  • 19 Feb, 2024
  • 1 location
Infigratinib in Recurrent Glioblastoma Patients

This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed …

hysterectomy
FGFR3
conjugated bilirubin
hair thinning
peripheral neuropathy
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

This trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers. A customized neuro-imaging referenced symptom video that describes symptoms and side effects specific to the patients' tumor may result in an early and sustained reduction in anxiety …

cancer
who grade iii glioma
MRI
who grade ii glioma
glioma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease.

  • 0 views
  • 19 Feb, 2024
  • 3 locations
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.

A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.

glioma
white blood cell count
ejection fraction
glioblastoma multiforme
temozolomide
  • 0 views
  • 19 Feb, 2024
  • 2 locations